0001772028 false 0001772028 2021-09-26 2021-09-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 26, 2021

 

SCOPUS BIOPHARMA INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-39788   82-1248020

(State or other jurisdiction of

incorporation or organization)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

420 Lexington Avenue, Suite 300

New York, New York 10170

(Address of principal executive offices)

 

(212) 479-2513

(Registrant’s telephone number, including area code)

 

 N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.001 par value   SCPS   The Nasdaq Stock Market LLC (Nasdaq Global Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

  

Item 1.01 Entry into a Material Definitive Agreement.

 

On September 26, 2021, a Special Committee of the Board of Directors (the “Board”) of Scopus BioPharma Inc. (the “Company”), upon the recommendation of the Audit Committee of the Board, approved an indemnification agreement (the “Indemnification Agreement”), pursuant to which the Company has agreed to indemnify each of HCFP (“HCFP”) and its affiliates, including Ira Scott Greenspan, Joshua Lamstein and Robert Gibson and entities under the common control of HCFP, Messrs. Greenspan, Lamstein or Gibson or its other affiliates (collectively, the “Indemnified Parties”) from and against any losses, claims, damages or liabilities, including reasonable attorney’s fees, suffered or incurred by the Indemnified Parties in connection with any disputes, litigation or threatened litigation (whether existing prior to or commencing after the date of the Indemnification Agreement) (i) involving Ashish Sanghrajka or Paul Hopper, each of whom is a member of the Board, and any of the Indemnified Parties, (ii) involving Morris C. Laster, MD, including relating to Dr. Laster’s purported ownership of certain of the Company’s shares of common stock and (iii) arising or resulting from any Indemnified Party’s affiliation or involvement with the Company, including in connection with the provision of additional services beyond those initially contemplated under the management services agreement between the Company and HCFP, regardless of whether such involvement or affiliation was caused by virtue of the fact that the Indemnified Party was acting as an officer of the Company and, in each case contemplated by this clause (iii), subject to the limitations contained in the Company’s Certificate of Incorporation and the Delaware General Corporation Law. The Indemnification Agreement also provides that the Company will advance expenses to any Indemnified Party, including legal fees, incurred by such Indemnified Party in connection with any litigation or proceeding to which such Indemnified Party is entitled to indemnification under the Indemnification Agreement. The foregoing summary of the Indemnification Agreement is qualified in its entirety by reference to the Indemnification Agreement, a copy of which is attached hereto as Exhibit 10.21 and incorporated herein by reference.

 

Item 8.01 Other Events.

 

On September 27, 2021, the Delaware Court of Chancery approved a stipulation between the Company and Dr. Laster in connection with Dr. Laster’s pending claims against the Company in the Delaware Court of Chancery (the “Delaware Matter”), pursuant to which (i) the Company agreed to voluntarily dismiss the interpleader lawsuit that it filed in the United States District Court for the Southern District of New York, (ii) Dr. Laster agreed to withdraw his motion to compel, motion to expedite and motion for a preliminary injunction in the Delaware Matter, (iii) the parties agreed that the Company will convene, and then immediately adjourn, the Company’s scheduled October 8, 2021 Annual Meeting of Stockholders (the “Annual Meeting”) such that the Annual Meeting will be held and the vote on the items of business to be considered at the Annual Meeting will be taken no earlier than 14 days and no later than 30 days after a decision on the merits or a final settlement between the parties, and the record date for the Annual Meeting will remain August 16, 2021, (iv) the parties agreed to cause all shares of the Company’s common stock held by them to be present in person or by proxy at the Annual Meeting and any adjournments thereof exclusively for purposes of establishing a quorum at the Annual Meeting and (v) the parties agreed to an expedited timeline for resolving the Delaware Matter with a trial intended to be held in December 2021.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No. Description

 

10.21 Indemnification Agreement, dated as of September 26, 2021
   
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

  

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  SCOPUS BIOPHARMA INC.
   
Dated: September 30, 2021 By: /s/ Joshua R. Lamstein
    Joshua R. Lamstein
    Chairman

  

 

 

 

Exhibit 10.21

 

Execution Copy

  

INDEMNIFICATION AGREEMENT

 

THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made as of September 26, 2021 (the “Effective Date”), by and among HCFP/Portfolio Services LLC, a Delaware limited liability company (“HCFP”), Scopus BioPharma Inc., a Delaware corporation (the “Company”), and HCFP’s principals, Ira Greenspan, Joshua Lamstein, and Robert Gibson (together, the “Principals”).

 

WITNESSETH:

 

WHEREAS HCFP and the Company entered into a Management Service Agreement dated September 1, 2017 (the “MSA”) pursuant to which HCFP agreed to provide management services to the Company;

 

WHEREAS the Principals and HCFP have provided the services contemplated under the MSA, which contemplated employing a separate Chief Executive Officer (“CEO”) and included supporting the CEO (the “Services”);

 

WHEREAS, in addition to providing the Services, HCFP and the Principals have provided, and continue to provide, additional services beyond what was initially contemplated under the MSA, including, but not limited to, managing the day-to-day operations of the Company (“Additional Services”);

 

WHEREAS, the Company recognizes the increased risk of litigation faced by HCFP and the Principals as a result of the Additional Services that HCFP and the Principals have provided and continue to provide to the Company; and

 

WHEREAS in consideration of the additional benefits obtained by the Company from the Additional Services, the Company wishes to provide an appropriate level of protection for the increased risk of litigation faced by HCFP and the Principals by agreeing to the additional indemnification provided herein.

 

NOW, THEREFORE, in consideration of the promises and the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows.

 

1. Indemnification.

 

(a)                The Company shall indemnify and hold harmless the Principals, HCFP, and HCFP’s affiliates (including, but not limited to, entities under HCFP’s and/or the Principals’ common control), subsidiaries, directors, officers, employees, partners, members, agents, successors and assigns (the “HCFP Affiliates”) (together, the “Indemnified Parties”) for and against any and all demands, suits, penalties, fines, liens, judgments, obligations, damages, claims, losses, liabilities, payments, costs and expenses, including legal, accounting and other expenses in connection therewith and costs and expenses incurred in connection with investigations and settlement proceeds (collectively, “Losses”) suffered or incurred by the Indemnified Parties, arising out of, attributable to, based upon, in connection with or resulting from:

 

 

 

 

(i)                 any disputes, litigation, or threatened litigation that exist prior to or commence after the Effective Date of this Agreement involving Dr. Morris C. Laster, including but not limited to, the purported ownership of certain of the Company’s shares (the “Disputed Shares”) as disclosed in Dr. Laster’s April 1, 2021 Schedule 13D filing with the U.S. Securities & Exchange Commission (“Share Ownership Dispute” and, collectively, the “Laster Dispute”);

 

(ii)              any disputes, litigation, or threatened litigation that exist prior to or commence after the Effective Date of this Agreement involving Ashish Sanghrajka and any of the Indemnified Parties (“Sanghrajka Dispute”); and

 

(iii)            any disputes, litigation, or threatened litigation that exist prior to or commence after the Effective Date of this Agreement involving Paul Hopper and any of the Indemnified Parties (“Hopper Dispute”); and

 

(iv)             any disputes, litigation, or threatened litigation that exist prior to or commence after the Effective Date of this Agreement arising or resulting from any of the Indemnified Parties’s affiliation with or inolvement with the Company, including but not limited to, in connection with the provision of Additional Services, regardless of whether that involvement or affiliation was caused by or by virtue of the fact that the Indemnified Party was acting as an officer of the Company, in each case contemplated by this clause (iv), subject to the limitations contained in the Company’s certificate of incorporation and the Delaware General Corporatiion Law (“Service Dispute”).

 

Notwithstanding the foregoing, nothing in this Agreement shall limit, supersede, or eliminate any indemnification rights or obligations of HCFP or the Principals and the Company already existing under the MSA, the Company’s bylaws, or the certificate of incorporation.

 

2. Advancement of Fees.

 

(a)                If any of the Indemnified Parties becomes a party to a litigation or proceeding or are otherwise involved in any way in any Service Dispute, Share Ownership Dispute, Laster Dispute, Sanghrajka Dispute and/or Hopper Dispute, the Company shall advance any and all expenses incurred in connection therewith (the “Advanced Fees”) to each Indemnified Party, including but not limited to legal fees, incurred by the Indemnified Party in connection with the disputes (the “Expenses”). The Company shall advance any and all Expenses within thirty days of an Indemnified Party’s written request.

 

3. Indemnification for Expenses Incurred in Enforcing Rights.

 

The Company shall indemnify the Indemnified Parties against any and all Expenses that are incurred by the Indemnified Parties in connection with any action brought by the

  

Indemnified Parties for indemnification or advance payment of Expenses by the Company under this Agreement or any other agreement or under applicable law.

 

- 2 -

 

 

4. Notice of Loss.

 

(a)               Each Indemnified Party shall give the Company, as applicable, written notice of any claim, event or matter that such Indemnified Party believes has given or will give rise to a right of indemnification under this Agreement, as promptly as practicable after such Indemnified Party receives notice of such claim, event or matter; provided that the failure to provide such notice shall not release the Company from any of its obligations under this Agreement except to the extent that the Company is materially prejudiced by such failure.

 

5. Notices.

 

All notices or communications made or sent in connection with this Agreement shall be in writing and shall be personally delivered or sent by registered or certified mail, return receipt requested, postage prepaid, to the parties at the following addresses:

 

If to the Company: Scopus BioPharma Inc.

420 Lexington Avenue, Suite 300

New York, New York 10170

 

If to HCFP: HCFP

420 Lexington Avenue, Suite 300

New York, NY 10170

 

If to Ira Greenspan: Ira Scott Greenspan

420 Lexington Avenue, Suite 300

New York, NY 10170

 

If to Joshua Lamstein: Joshua Lamstein

420 Lexington Avenue, Suite 300

New York, NY 10170

 

If to Robert Gibson: Rob Gibson

420 Lexington Avenue, Suite 300

New York, NY 10170

  

- 3 -

 

  

6. Miscellaneous.

 

(a)               This Agreement may be modified or amended only by an agreement in writing signed by HCFP, the Principals and the Company. No waiver of any term or provision hereof shall be effective unless in a writing signed by the party waiving such term or provision.

 

(b)               If any provision of this Agreement or the application thereof to any party or circumstance shall be held to be invalid, illegal, unenforceable, or inconsistent with any present or future law, ruling, rule, or regulation of any court or governmental or regulatory authority having jurisdiction over the subject matter of this Agreement, such provision shall be rescinded or modified in accordance with such law, ruling, rule, or regulation, and the remainder of this Agreement, or the application of such provision to the parties or circumstances other than those as to which it is held inconsistent, shall not be affected thereby and shall be enforced to the greatest extent permitted by law.

 

(c)               This Agreement may be executed in one or more counterparts, all of which taken together shall constitute a single agreement.

 

(d)               Any headings herein are inserted for convenience of reference only and shall be ignored in the construction and interpretation hereof.

 

(e)                This Agreement and all acts and transactions pursuant hereto shall be governed, construed and interpreted in accordance with the laws of the State of New York, without giving effect to its principles of conflicts of law. The parties hereby consent to resolve any dispute arising hereunder by submission of such dispute to binding arbitration

 

under the auspices of the American Arbitration Association (“AAA”) in New York City under the Commercial Arbitration Rules of the AAA before a panel of three arbitrators selected from the panels of arbitrators of the AAA; provided that one arbitrator shall be selected by the Company, the second arbitrator shall be selected by one of the Indemnified Parties, and the third arbitrator shall be selected by the two previously selected arbitrators. Notwithstanding anything herein contained to the contrary, (i) the parties hereto shall be permitted to seek injunctive relief from any court having jurisdiction over the subject matter hereof in furtherance of any such party’s rights hereunder, (ii) the parties hereto shall have the right to seek enforcement of any arbitration award by any court having jurisdiction over the award and (iii) the parties hereto hereby consent to the jurisdiction of any United States Federal court or State court located in the Borough of Manhattan, The City of New York in connection with clauses (i) and (ii) of this Section 6(e). Each of the parties hereto acknowledges that if it fails to perform any of its obligations under this Agreement, immediate and irreparable harm or injury would be caused to the other parties hereto for which money damages would not be an adequate remedy. In such event, the parties hereto agree that each party hereto shall have the right, in addition to any other rights it may have, to immediate injunctive relief without proof of actual damages or the posting of bond or other security. Accordingly, if any party hereto should institute an action or proceeding seeking such equitable relief, the other parties hereto hereby waive the claim or defense that any such party hereto has an adequate remedy at law and hereby agree not to assert in any such action or proceeding the claim or defense that such a remedy at law exists. The parties hereto further agree to waive any requirements for the securing or posting of any bond in connection with obtaining any such equitable relief.

 

- 4 -

 

 

(f) This Agreement, including the indemnification obligations of the parties hereto, shall not be deemed to be exclusive of any other rights to which any Indemnified Party may be entitled at law or in equity and shall inure to the benefit of the heirs, successors and administrators of such Indemnified Parties.

  

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

  

- 5 -

 

 

 

IN WITNESS WHEREOF, the parties have executed this Agreement on the date first written above.

 

  HCFP/Portfolio Services LLC
   
  By: /s/ rOBERT J.GIBSON
    Name: ROBERT J. GIBSON
    Title: MANAGING DIRECTOR

  

  Scopus BioPharma Inc
   
  By: /s/ Joshua R. Lamstein
    Name: Joshua R. Lamstein
    Title: Chairman

 

  Ira Scott Greenspan
   
  By: /s/ Ira Scott Greenspan
    Name: Ira Scott Greenspan
    Title: Individual

  

  Joshua Lamstein
   
  By: /s/ Joshua R. Lamstein
    Name: Joshua Lamstein
    Title: Individual

 

  Robert Gibson
   
  By: /s/ Robert J.Gibson
    Name: ROBERT J. GIBSON
    Title: INDIVIDUAL